Genentech Reports Strong Phase 3 Enspryng Data in MOGAD

South San Francisco, California, USA – April 21, 2026

In a major breakthrough for rare neurological diseases, Genentech has announced positive Phase 3 results for Enspryng® (satralizumab), demonstrating a 68% reduction in relapse risk in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The findings, presented at the American Academy of Neurology (AAN) 2026 Annual Meeting, mark a pivotal step toward what could become the first approved therapy for this debilitating autoimmune condition, which currently has no approved treatment options.

Phase 3 Data Demonstrates Strong Clinical Benefit

The Phase 3 METEOROID study met its primary endpoint, showing that treatment with Enspryng significantly delayed the time to first relapse compared to placebo. At 48 weeks, 87% of patients receiving Enspryng remained relapse-free, compared to 67% in the placebo group, with clinical benefits observed as early as eight weeks.

Additionally, the therapy reduced the annualized relapse rate (ARR) by 66%, a key secondary endpoint, reinforcing its potential to prevent disease progression and long-term neurological damage. Given that MOGAD is characterized by unpredictable and severe relapses affecting the optic nerves, brain, and spinal cord, these results represent a meaningful advancement in disease management.

Further analyses showed that Enspryng significantly reduced central nervous system inflammation, with a 79% reduction in active MRI lesions, and decreased reliance on rescue therapies such as steroids and plasma exchange by 73%, highlighting its comprehensive therapeutic impact.

Novel Mechanism Targets Underlying Disease Biology

MOGAD is a rare autoimmune disorder of the central nervous system, often leading to vision loss, disability, and cumulative neurological damage due to repeated inflammatory attacks. Currently, treatment options are limited to off-label therapies that primarily manage symptoms rather than addressing the root cause.

Enspryng works as a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, a key driver of inflammation and autoantibody production in autoimmune diseases. By blocking IL-6 signaling, the therapy helps reduce pathogenic antibody levels, suppress inflammatory T-cell activity, and restore blood-brain barrier integrity, offering a targeted and disease-modifying approach.

The drug is already approved in over 90 countries for neuromyelitis optica spectrum disorder (NMOSD), and its established safety profile supports its expansion into additional neurological indications.

Regulatory Pathway and Future Outlook

The strong Phase 3 results position Enspryng as a potential first-in-class treatment for MOGAD, with regulatory submissions planned globally following the METEOROID study outcomes. The therapy has already received orphan drug designation for MOGAD, reflecting the urgent need for effective treatments in this rare disease population.

Importantly, the safety profile observed in the study was consistent with previous clinical experience, with no new safety signals identified. Common adverse events included injection-related reactions, influenza, and mild infections, with low discontinuation rates, supporting its suitability for long-term use.

Beyond MOGAD, Genentech continues to expand Enspryng’s development across multiple autoimmune conditions, including autoimmune encephalitis and thyroid eye disease, reinforcing its role as a versatile immunology platform therapy.

As the field of neurology increasingly shifts toward targeted immunotherapies, Enspryng’s success underscores the potential of IL-6 inhibition in treating complex autoimmune diseases. If approved, the therapy could transform the standard of care for MOGAD, offering patients a first-ever evidence-based treatment that reduces relapses, preserves neurological function, and improves long-term outcomes.

This milestone highlights Genentech’s continued leadership in innovative neuroscience research, delivering precision therapies that address the underlying mechanisms of rare and debilitating diseases.

Source: Genentech press release